Evidence map›Paper›PMID 39699934›Full record

ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2025

Certolizumab pegol for plaque psoriasis in women of childbearing potential, pregnant or breastfeeding in clinical settings: One-year outcomes from the international noninterventional CIMREAL study.

Tom Hillary, Fiona Lovegrove, Thierry Boye, Evangelia Papadavid, Luca Bianchi, Ángeles Flórez Menéndez, Alberto Barea, Frederik Fierens, Ines Dueñas Pousa, Jackie Hee and 2 more

Abstract readLetter
In one paragraph

Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tom HillaryDepartment of Dermatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0002-4497-8487
Fiona LovegroveSchulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Thierry BoyeHIA, Hôpital Sainte Anne, Toulon, France.
Evangelia PapadavidDepartment of Dermatology, National and Kapodistrian University of Athens Medical School, Athens, Greece.ORCID https://orcid.org/0000-0002-8634-102X
Luca BianchiDepartment of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.ORCID https://orcid.org/0000-0001-8697-6896
Ángeles Flórez MenéndezDepartment of Dermatology, Pontevedra University Hospital, Pontevedra, Spain.
Alberto BareaConsultant Nurse in Dermatology at Kingston Hospital, London, UK.
Frederik FierensUCB Pharma, Brussels, Belgium.
Ines Dueñas PousaUCB Pharma, Madrid, Spain.
Jackie HeeUCB Pharma, Morrisville, North Carolina, USA.
Paulette WilliamsUCB Pharma, Morrisville, North Carolina, USA.
Khusru AsadullahDepartment of Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany.

Funding

UCB Pharma
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39699934
PMCPMC12105429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.